Upregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients with Ovarian Cancer

Table 1

Characteristics of patients with ovarian serous cystadenocarcinoma obtained from TCGA data.

Characteristic	Low expression of CYBRD1	High expression of CYBRD1
N	188	188
FIGO stage, n (%)			0.951
Stage I	1 (0.3%)	0 (0%)
Stage II	11 (2.9%)	11 (2.9%)
Stage III	145 (38.9%)	148 (39.7%)
Stage IV	30 (8%)	27 (7.2%)
Primary therapy outcome, n (%)			0.017
PD	12 (3.9%)	15 (4.9%)
SD	7 (2.3%)	15 (4.9%)
PR	17 (5.6%)	26 (8.5%)
CR	124 (40.7%)	89 (29.2%)
Age, n (%)			1.000
≤60	104 (27.7%)	103 (27.4%)
>60	84 (22.3%)	85 (22.6%)
Anatomic neoplasm subdivision, n (%)			0.201
Unilateral	57 (16.1%)	44 (12.4%)
Bilateral	122 (34.5%)	131 (37%)
Venous invasion, n (%)			0.623
No	25 (24.3%)	15 (14.6%)
Yes	35 (34%)	28 (27.2%)
Lymphatic invasion, n (%)			0.845
No	27 (18.2%)	21 (14.2%)
Yes	53 (35.8%)	47 (31.8%)
Tumor residual, n (%)			0.410
NRD	36 (10.8%)	30 (9%)
RD	128 (38.4%)	139 (41.7%)
OS event, n (%)			0.112
Alive	81 (21.5%)	65 (17.3%)
Dead	107 (28.5%)	123 (32.7%)
DSS event, n (%)			0.074
Alive	85 (24.2%)	67 (19.1%)
Dead	91 (25.9%)	108 (30.8%)
Age, median (IQR)	58 (50, 67)	59 (51, 68)	0.627